Loading…
The company plans to halt all clinical trials for nemvaleukin.
Mural Oncology plc (NASDAQ: MURA) announced on April 15, 2025, its decision to discontinue all clinical development of nemvaleukin and explore strategic alternatives. The company cited a comprehensive review of its pipeline and strategic options as the reason for this decision.
Mural Oncology reported that it holds $144.4 million in cash and equivalents, with 90% of its free float available for strategic considerations. The company did not provide further details on the nature of the strategic alternatives being explored.
As of the latest data, Mural Oncology has a free float of 14,346,800 shares and 17,344,500 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.